Summary
Modern treatment of mental depression started with the availability of monoamine oxidase (MAO) inhibitors and tricyclic antidepressants. These drugs also contributed to the early development of psychopharmacology. Attempts to improve the anti-tuberculous action of the hydrazine derivative isoniazid by developing derivatives thereof led to the synthesis of iproniazid. Its introduction as the first modern antidepressant was based on three unexpected actions of the drug: MAO-inhibition, ‘reversal’ of reserpine-induced sedation, and the presence of psychostimulation as a clinical side effect in man. However, the initial success of iproniazid and other MAO inhibitors, hydrazides and non-hydrazides, was curtailed by the occurrence of undesirable side effects such as potentiation of the blood-pressure elevating action of food amines. The tricyclic antidepressants were a development of the class of antihistamines, one of which, chlorpromazine, showed neuroleptic activity. A congener of this compound, imipramine, was discovered by clinical observation to have unexpected antidepressant effects. The clinical success of this drug (which is still in use) led to the development of a successful series of other tricyclic and non-tricyclic antidepressants. Progress in the elucidation of possible mechanisms of the action of the tricyclic compounds has helped this development. Recent advances in basic research have also induced a revival of MAO-inhibitors since, due to the discovery of MAO-subtypes, inhibitors with higher specificity and fewer undesirable side effects are now available.
Similar content being viewed by others
Literatur
Ayd, F.J., and Blackwell, B., Discoveries in Biological Psychiatry. J. B. Lippincott, Philadelphia/Toronto 1970.
Bein, J. J., The pharmacology of Rauwolfia. Pharmac. Rev.8 (1956) 435–483.
Bernstein, J., Lott, W. A., Steinberg, B. A., and Yale, H. L., Chemotherapy of experiemental tuberculosis. V. Isonicotinic acid hydrazide (Nydrazid) and related compounds. Am. Rev. Tuberculosis65 (1952) 357–364.
Bogdanski, D. F., Pletscher, A., Brodie, B. B., and Udenfried, S., Identification and assay of serotonin in brain. J. Pharmac. exp. Ther.117 (1956) 82–88.
Brodie, B. B., Pletscher, A., and Shore, P. A., Possible role of serotonin in brain function and reserpine action. J. Pharmac. exp. Ther.111 (1956) 9.
Cade, J. F. J., The story of lithium, in: Discoveries in Biological Psychiatry, pp. 218–229. Eds F. J. Ayds and B. Blackwell. J. B. Lippincott, Philadelphia/Toronto 1970.
Carlsson, A., and Lindqvist, M., Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta pharmac. toxic.20 (1963) 140–144.
Charpentier, P., Sur la constitution d'un diméthylamino-N-phenothiazine, C. r. hebd. Séanc. Acad. Sci.225 (1947) 306–308.
Chessin, M., Dubnick, B., Kramer, E. R., and Scott, C. C., Modification of pharmacology of reserpine and serotonin by iproniazid. Fedn Proc.15 (1956) 409.
Courvoisier, S., Fournel, J., Ducrot, M., Kolsky, M., and Koetschet, P., Propriétés pharmacodynamiques du chlorhydrate de chloro-3-(diméthylamino-3-propyl)-10-phénothiazine (4.560 R.P.). Archs int. pharmacodyn.92 (1953) 305–361.
Delay, J., Deniker, P., and Harl, J. M., Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective (4560 R). Annls méd.-psychol.110 pt. 2 (1952) 112–117.
Fox, H. H., and Gibas, J. T., Synthetic tuberculostats. VII. Monoalkyl derivates of isonicotinylhydrazine. J. org. Chem.18 (1953) 994–1002.
Grunberg, E., and Schnitzer, R. J., Studies on the activity of hydrazine derivatives of isonicotinic acid in the experimental tuberculosis of mice. Quart. Bull. Sea View Hospital13 (1952) 3–11.
Hoffmann, A., The discovery of LSD and subsequent investigations on naturally occurring hallucinogens, in: Discoveries in Biological Psychiatry, pp. 91–106. Eds F. J. Ayd and B. Blackwell, J. B. Lippincott, Philadelphia/Toronto 1970.
Kamman, G. R., Freeman, J. G., and Lucero, R. J., The effect of 1-isonicotinyl-2-isopropyl hydrazide (IIH) on the behaviour or long-term mental patients. J. nerv. ment. Dis.118 (1953) 391–407.
Kuhn, R., Die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz. med. Wschr.87 (1957) 1135–1140.
Kuhn, R., The imipramine story, in: Discoveries in Biological Psychiatry, pp. 205–217. Eds F. J. Ayd and B. Blackwell, J. B. Lippincott, Philadelphia/Toronto 1970.
Laborit, H., Therapeutique neuroplégique et hibernation artificielle: essai d'éclairissement d'une équivoque. Presse med.G2 (1954) 359–362.
Lehmann, H. E., and Kline, N. S., Clinical discoveries with antidepressant drugs, in: Discoveries in Pharmacology, vol.1: Psycho- and Neuropharmacology, pp. 209–247. Eds M. J. Parnham and J. Brunivels. Elsevier Science Publishers, B. V. 1983.
Loomer, H. P., Saunders, J. C., and Kline, N. S., Iproniazid, an amine oxidase inhibitor, as an example of a psychic energizer. Congr. Rec. (1957) 1382–1390.
Loomer, H. P., Saunders, J. C., and Kline, N. S., A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat. Res. Rep. Am. psychiat. Ass.8 (1958) 129–141.
Otte, H. A., Siefken, W., and Domagk, G., Neoteben, ein neues, hochwirksames Tuberkulostatikum und die Beziehungen zwischen Konstitution und tuberkulostatischer Wirksamkeit von Hydrazinderivaten. Naturwissenschaften39 (1952) 118.
Pletscher, A., Shore, P. A., and Brodie, B. B., Serotonin as a mediator of reserpine action in brain. J. Pharmac. exp. Ther.116 (1956) 84–89.
Pletscher, A., Gey, K. F., and Zeller, P., Monoaminooxydase-Hemmer: Biochemie, Chemie, Pharmakologie, Klinik, in: Progress in Drug Research, vol. 2, pp. 417–590. Ed. E. Jucker. Birkhäuser Verlag, Basel/Stuttgart 1960.
Sandler, M., Monoamine oxidase inhibitors in depression: History and mythology. J. Psychopharmac.4 (1990) 136–139.
Smith, J. A., The use of the isopropylderivative of isonicotinylhydrazine (Marsilid) in the treatment of mental disease. Am. Practitioner4 (1953) 519–520.
Sneader, W., Drug Discovery: The Evolution of Modern Medicines. John Wiley and Sons, New York 1985.
Sulser, F., and Mishra, R., The discovery of tricyclic antidepressants and their mode of action, in: Discoveries in Pharmacology, vol. 1: Psycho- and Neuropharmacology, pp. 233–247. Eds M. J. Parnham and J. Brunivels. Elsevier Science Publishers B. V. 1983.
Zeller, E. A., and Barsky, J., In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc. Soc. exp. Biol. N.Y.81 (1952) 459–461.
Zeller, E. A., Barsky, J., Berman, E. R., and Fouts, J. R., Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system. J. Pharmac. exp. Ther.106 (1952) 427–428.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pletscher, A. The discovery of antidepressants: A winding path. Experientia 47, 4–8 (1991). https://doi.org/10.1007/BF02041242
Issue Date:
DOI: https://doi.org/10.1007/BF02041242